Drug Development Pharma - February 23, 2016
AZ’s Brilique approved in EU for extended treatment of patients with history of heart attack
AstraZeneca has announced that the European Commission has granted marketing authorisation for Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event. Treatment may be started as continuation therapy after an initial […]
